Back to Journals » Lung Cancer: Targets and Therapy » Volume 1 » Default

Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines

Authors Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C, MacBeth KJ

Published 10 September 2010 Volume 2010:1 Pages 119—140


Review by Single anonymous peer review

Peer reviewer comments 3

Aaron N Nguyen1, Paul W Hollenbach1, Normand Richard2, Antonio Luna-Moran1, Helen Brady2, Carla Heise1, Kyle J MacBeth1
1Celgene Corporation, San Francisco, CA, USA; 2Celgene Corporation, San Diego, CA, USA

Abstract: Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in solid tumors. To better understand the mechanism of action of these drugs, we examined the effects of AZA and DAC in a panel of non-small cell lung cancer (NSCLC) cell lines. Of 5 NSCLC lines tested in a cell viability assay, all were sensitive to AZA (EC50 of 1.8–10.5 µM), while only H1299 cells were equally sensitive to DAC (EC50 of 5.1 µM). In the relatively DAC-insensitive cell line A549, both AZA and DAC caused DNA methyltransferase I depletion and DNA hypomethylation; however, only AZA significantly induced markers of DNA damage and apoptosis, suggesting that mechanisms in addition to, or other than, DNA hypomethylation are important for AZA-induced cell death. Cell cycle analysis indicated that AZA induced an accumulation of cells in sub-G1 phase, whereas DAC mainly caused an increase of cells in G2/M. Gene expression analysis of AZA- and DAC-treated cells revealed strikingly different profiles, with many genes distinctly regulated by each drug. In summary, while both AZA and DAC caused DNA hypomethylation, distinct effects were demonstrated on regulation of gene expression, cell cycle, DNA damage, and apoptosis.

Keywords: apoptosis, azacitidine, decitabine, gene expression, non-small cell lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.